[Medical problems in the practical execution of drug testing]

Area of Science:

• Clinical Pharmacology
• Drug Development
• Biostatistics

Background:

• Clinical trial design must be substance-specific, accounting for minor variations in effects.
• Early-phase (Phase I) trials face challenges in volunteer selection, dosage, and administration routes.
• Later-phase trials (Phases II-IV) focus on controlled studies, including standard treatments, placebo comparisons, and patient compliance.

Purpose of the Study:

• To outline the distinct experimental designs required for individual substances in clinical trials.
• To identify common difficulties encountered during Phase I, II, III, and IV clinical trials.
• To address the perception of danger associated with clinical trials.

Main Methods:

• Review of experimental design considerations for various clinical trial phases.
• Identification of common challenges in participant selection, dosing, and administration.
• Analysis of factors influencing controlled clinical trials, such as standard treatments and patient compliance.

Main Results:

• Substance-specific designs are crucial, even for closely related compounds.
• Phase I trials present unique challenges in human administration and dosage escalation.
• Controlled clinical trials involve complex factors like placebo use and patient adherence.

Conclusions:

• Clinical trial design is highly individualized based on substance properties.
• Addressing logistical and ethical challenges is key to successful early-phase trials.
• Data suggests clinical trials are not exceptionally dangerous, contrary to popular belief.